169 related articles for article (PubMed ID: 9303391)
1. Penetration of GS4071, a novel influenza neuraminidase inhibitor, into rat bronchoalveolar lining fluid following oral administration of the prodrug GS4104.
Eisenberg EJ; Bidgood A; Cundy KC
Antimicrob Agents Chemother; 1997 Sep; 41(9):1949-52. PubMed ID: 9303391
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of influenza virus infections in mice by GS4104, an orally effective influenza virus neuraminidase inhibitor.
Sidwell RW; Huffman JH; Barnard DL; Bailey KW; Wong MH; Morrison A; Syndergaard T; Kim CU
Antiviral Res; 1998 Feb; 37(2):107-20. PubMed ID: 9588843
[TBL] [Abstract][Full Text] [Related]
3. Identification of GS 4104 as an orally bioavailable prodrug of the influenza virus neuraminidase inhibitor GS 4071.
Li W; Escarpe PA; Eisenberg EJ; Cundy KC; Sweet C; Jakeman KJ; Merson J; Lew W; Williams M; Zhang L; Kim CU; Bischofberger N; Chen MS; Mendel DB
Antimicrob Agents Chemother; 1998 Mar; 42(3):647-53. PubMed ID: 9517946
[TBL] [Abstract][Full Text] [Related]
4. Metabolism of the influenza neuraminidase inhibitor prodrug oseltamivir in the rat.
Sweeny DJ; Lynch G; Bidgood AM; Lew W; Wang KY; Cundy KC
Drug Metab Dispos; 2000 Jul; 28(7):737-41. PubMed ID: 10859145
[TBL] [Abstract][Full Text] [Related]
5. Oseltamivir.
Bardsley-Elliot A; Noble S
Drugs; 1999 Nov; 58(5):851-60; discussion 861-2. PubMed ID: 10595865
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the anti-influenza virus activity of RWJ-270201 with those of oseltamivir and zanamivir.
Bantia S; Parker CD; Ananth SL; Horn LL; Andries K; Chand P; Kotian PL; Dehghani A; El-Kattan Y; Lin T; Hutchison TL; Montgomery JA; Kellog DL; Babu YS
Antimicrob Agents Chemother; 2001 Apr; 45(4):1162-7. PubMed ID: 11257030
[TBL] [Abstract][Full Text] [Related]
7. The neuraminidase inhibitor GS4104 (oseltamivir phosphate) is efficacious against A/Hong Kong/156/97 (H5N1) and A/Hong Kong/1074/99 (H9N2) influenza viruses.
Leneva IA; Roberts N; Govorkova EA; Goloubeva OG; Webster RG
Antiviral Res; 2000 Nov; 48(2):101-15. PubMed ID: 11114412
[TBL] [Abstract][Full Text] [Related]
8. Lack of pharmacokinetic interaction between the oral anti-influenza neuraminidase inhibitor prodrug oseltamivir and antacids.
Snell P; Oo C; Dorr A; Barrett J
Br J Clin Pharmacol; 2002 Oct; 54(4):372-7. PubMed ID: 12392584
[TBL] [Abstract][Full Text] [Related]
9. High-performance liquid chromatographic determination of GS4071, a potent inhibitor of influenza neuraminidase, in plasma by precolumn fluorescence derivatization with naphthalenedialdehyde.
Eisenberg EJ; Cundy KC
J Chromatogr B Biomed Sci Appl; 1998 Sep; 716(1-2):267-73. PubMed ID: 9824240
[TBL] [Abstract][Full Text] [Related]
10. Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802.
He G; Massarella J; Ward P
Clin Pharmacokinet; 1999 Dec; 37(6):471-84. PubMed ID: 10628898
[TBL] [Abstract][Full Text] [Related]
11. Immunological effects of the orally administered neuraminidase inhibitor oseltamivir in influenza virus-infected and uninfected mice.
Burger RA; Billingsley JL; Huffman JH; Bailey KW; Kim CU; Sidwell RW
Immunopharmacology; 2000 Apr; 47(1):45-52. PubMed ID: 10708809
[TBL] [Abstract][Full Text] [Related]
12. New approaches to influenza chemotherapy. Neuraminidase inhibitors.
Calfee DP; Hayden FG
Drugs; 1998 Oct; 56(4):537-53. PubMed ID: 9806102
[TBL] [Abstract][Full Text] [Related]
13. Increasing oral absorption of polar neuraminidase inhibitors: a prodrug transporter approach applied to oseltamivir analogue.
Gupta D; Varghese Gupta S; Dahan A; Tsume Y; Hilfinger J; Lee KD; Amidon GL
Mol Pharm; 2013 Feb; 10(2):512-22. PubMed ID: 23244438
[TBL] [Abstract][Full Text] [Related]
14. Oral administration of a prodrug of the influenza virus neuraminidase inhibitor GS 4071 protects mice and ferrets against influenza infection.
Mendel DB; Tai CY; Escarpe PA; Li W; Sidwell RW; Huffman JH; Sweet C; Jakeman KJ; Merson J; Lacy SA; Lew W; Williams MA; Zhang L; Chen MS; Bischofberger N; Kim CU
Antimicrob Agents Chemother; 1998 Mar; 42(3):640-6. PubMed ID: 9517945
[TBL] [Abstract][Full Text] [Related]
15. Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza.
Hayden FG; Atmar RL; Schilling M; Johnson C; Poretz D; Paar D; Huson L; Ward P; Mills RG
N Engl J Med; 1999 Oct; 341(18):1336-43. PubMed ID: 10536125
[TBL] [Abstract][Full Text] [Related]
16. Influenza.
Khare MD; Sharland M
Expert Opin Pharmacother; 2000 Mar; 1(3):367-75. PubMed ID: 11249523
[TBL] [Abstract][Full Text] [Related]
17. The pharmacokinetics and tolerability of the oral neuraminidase inhibitor oseltamivir (Ro 64-0796/GS4104) in healthy adult and elderly volunteers.
Massarella JW; He GZ; Dorr A; Nieforth K; Ward P; Brown A
J Clin Pharmacol; 2000 Aug; 40(8):836-43. PubMed ID: 10934667
[TBL] [Abstract][Full Text] [Related]
18. GS4071 is a slow-binding inhibitor of influenza neuraminidase from both A and B strains.
Kati WM; Saldivar AS; Mohamadi F; Sham HL; Laver WG; Kohlbrenner WE
Biochem Biophys Res Commun; 1998 Mar; 244(2):408-13. PubMed ID: 9514938
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of anti-influenza prodrug oseltamivir in children aged 1-5 years.
Oo C; Hill G; Dorr A; Liu B; Boellner S; Ward P
Eur J Clin Pharmacol; 2003 Sep; 59(5-6):411-5. PubMed ID: 12910331
[TBL] [Abstract][Full Text] [Related]
20. Zanamivir Amidoxime- and N-Hydroxyguanidine-Based Prodrug Approaches to Tackle Poor Oral Bioavailability.
Schade D; Kotthaus J; Riebling L; Kotthaus J; Müller-Fielitz H; Raasch W; Hoffmann A; Schmidtke M; Clement B
J Pharm Sci; 2015 Sep; 104(9):3208-19. PubMed ID: 26037932
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
